Professional Documents
Culture Documents
Press Release - JB Pharma
Press Release - JB Pharma
LAUNCH
Records revenue growth of 22% to INR 762 crores in Q4 FY23 & grew 30% to
INR 3149 crores in FY23 & operating EBITDA increased by 21% to INR 181
crores in Q4 FY23
5th June 2023: JB Pharma, the fastest growing company in the Indian pharmaceutical
market, today marks the one-year anniversary of the launch of their identity. Good People
for Good Health is a testament of the brands unwavering commitment to spreading good
health globally. Crossing the milestone, the company highlights their- journey of
contributions made towards Indian healthcare – of supporting healthcare providers and
enriching patients’ lives globally. This is reflected in three key elements which are – their
people, products, and financial results.
Sharing his views on the occasion, Mr. Nikhil Chopra, CEO & Whole-Time
Director, JB Pharma said, “While we touch new horizons, we are rooted in our values of
simplicity, reliability and agility that define us. We will continue to remain simple in our
actions, reliable in our relationships and agile in our approach towards effecting changing
scenarios in the healthcare industry.”
The organisation also announced their Q4FY23 financial results. The company recorded
revenue of INR 3,149 crores registering a growth of 30%. Operating EBITDA (Earnings
Before Interest Depreciation and Taxes) registered growth of 26% to INR 765 crores and
Profit after Tax was INR 410 crores recording a growth of 6%. JB maintained its upward
momentum with quarterly revenues at INR 762 crores recording a 22% increase, closing
the year in excess of INR 3000 crores, with FY23 recording a growth of 30% to INR 3149
crores.
The domestic formulations business clocked revenue of INR 380 crores recording a growth
of 29% for the quarter and was at INR 1640 crores for FY23 with a growth of 38%.
Rantac, Cilacar, Cilacar-T, Metrogyl, Nicardia, Azmarda and Sporlac drove up the
ranks to feature among the top 300 Indian Pharmaceutical Brands. JB Pharma ranks among
the top 10 players in the cardiology segment and among the top 15 by prescription.
JB Pharma develops innovative products under big brands like Rantac OD, RD, Ranraft,
Metrogyl ER, Metrogyl DG Gel, Nicardia XL, Sporlac EVA, Sporlac GG etc. to cater
to a wide patient profile in respective therapeutic categories. With Sporlac, JB Pharma is
the fastest growing among the top 3 brands in the probiotics segment in India.
The international business performed well and grew at 16% to INR 382 crores in the
quarter and 22% to INR 1509 crores for the financial year. CDMO (Contract Development &
Manufacturing Organisation) business closed the year with INR 400+ crores revenue
maintaining its INR 100 crores quarterly revenue run rate. In CDMO, the organisation is the
3rd largest manufacturer of herbal and medicated lozenges in the world. With 70+
products in different formats, flavours, shapes, and sizes even herbal &
medicated, lozenges cater to almost 7% of the world’s total population.
JB Pharma’s focus on their sustainability goals has also propelled the team to
significantly reduce emissions and work towards their sustainability goals for FY24.
They released their maiden sustainability report FY22 last year.
About JB Pharma:
Founded in 1976, the company has extended its reach beyond India and now operates in
Russia and South Africa as well. JB Pharma's success is reflected in its six brands among
the top 300 IPM brands in India, with much of its revenue coming from India. Additionally,
JB Pharma exports its finished formulations to over 40 countries, including the United
States.
The company exports its finished formulations to 40+ countries worldwide, including the
United States. JB is a leader in manufacturing medicated lozenges and ranks among the top
five manufacturers globally in the field of medicated and herbal lozenges. The company has
seven state-of-the-art manufacturing facilities in India, including a dedicated manufacturing
facility for lozenges, all of which are certified by leading regulators worldwide.
JB Pharma has established itself among the top 25 Indian Pharma Companies and
consistently outperforms the market, quarter on quarter.
Website: https://jbpharma.com/
LinkedIn: https://www.linkedin.com/company/j-b-global/mycompany/
Facebook: https://www.facebook.com/Onejbglobal/